167 related articles for article (PubMed ID: 12658893)
1. EGFR inhibitors: clinical results.
De Marinis F; Nelli F; D'Auria G
Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893
[No Abstract] [Full Text] [Related]
2. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Natale RB
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
[TBL] [Abstract][Full Text] [Related]
3. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
4. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib (Iressa) trials in non-small cell lung cancer.
Johnson DH
Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
7. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Bonomi P
Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
[TBL] [Abstract][Full Text] [Related]
8. Surprise phase III failure for ZD1839.
Wilkinson E
Lancet Oncol; 2002 Oct; 3(10):583. PubMed ID: 12372708
[No Abstract] [Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Penne K; Bohlin C; Schneider S; Allen D
Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
[TBL] [Abstract][Full Text] [Related]
11. What went wrong with Iressa?
Burton A
Lancet Oncol; 2002 Dec; 3(12):708. PubMed ID: 12473493
[No Abstract] [Full Text] [Related]
12. ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS; Kies MS
Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
15. ZD1839 (Iressa): for more than just non-small cell lung cancer.
Ranson M
Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
[TBL] [Abstract][Full Text] [Related]
16. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Lin CC; Yang CH
Target Oncol; 2009 Jan; 4(1):37-44. PubMed ID: 19343300
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K; Averbuch S
Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]